Physician profile
Sinead E Flood
NPI 1659990653
$2,625.05
in general payments reported to CMS, 2019-2025
13 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $143 · 2021: $139 · 2022: $301 · 2023: $1,516 · 2024: $133 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,190 · Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,189.58 |
| Food and Beverage | $853.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,792.70 | 2021-2025 | Air Optix, Dailies Aqua Comfort Plus, Dailies Total1 Multifocal |
| Johnson & Johnson Surgical Vision, INC. | $127.40 | 2025 | Tecnis Iol |
| Aerie Pharmaceuticals, INC. | $123.74 | 2020 | |
| Rxsight INC | $119.92 | 2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $118.26 | 2021 | |
| Apellis Pharmaceuticals, INC. | $103.60 | 2024 | Syfovre |
| Abbvie INC. | $56.62 | 2025 | |
| Dompe US, INC. | $46.76 | 2025 | Oxervate |
| Bausch & Lomb Americas INC. | $44.13 | 2022-2023 | Infuse |
| Harrow Eye, LLC | $29.86 | 2024 | Iheezo |
| Tarsus Pharmaceuticals, INC. | $24.97 | 2025 | Xdemvy |
| Alimera Sciences, INC. | $19.08 | 2020 | |
| Coopervision INC. | $18.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinead Flood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.